West Pharmaceutical Services (NYSE:WST) Issues Earnings Results

Key Points

• West Pharmaceutical Services beat third-quarter expectations: Revenue rose 8.7% year over year to $874.5 million, while adjusted EPS increased 36% to $2.66. The company raised its 2026 revenue guidance to $3.41–$3.42 billion and adjusted EPS guidance to $9.38–$9.48.
• High-Value Product Components drove growth and profitability: HVP sales increased nearly 20% organically, supported by strong GLP-1 demand, while gross and adjusted operating margins expanded substantially.
• Some challenges remain: West Vantage revenue declined 6.6% organically as legacy programs rolled off, free cash flow fell about 5% year to date, and the planned SmartDose divestiture is expected to weigh on reported growth in 2027.

West Pharmaceutical Services (NYSE:WST - Get Free Report) issued its quarterly earnings data on Thursday. The medical instruments supplier reported $2.66 earnings per share for the quarter, beating analysts' consensus estimates of $2.20 by $0.46, FiscalAI reports. The company had revenue of $874.50 million during the quarter, compared to analysts' expectations of $827.12 million. West Pharmaceutical Services had a return on equity of 20.11% and a net margin of 16.98%. The firm's revenue for the quarter was up 8.7% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.96 earnings per share.

Here are the key takeaways from West Pharmaceutical Services' conference call:

• Q3 results exceeded expectations: Revenue rose 8.7% reported and 11.9% organically to $874 million, while adjusted EPS increased 36% to $2.66. Management raised full-year 2026 revenue guidance to $3.41–$3.42 billion and adjusted EPS guidance to $9.38–$9.48.
• HVP and GLP-1 demand remained strong. HVP Components grew 20% organically, including GLP-1 growth well into the 30% range and high-teens growth outside GLP-1; the company also added more than 200 HVP upgrade projects this year.
• Profitability expanded significantly. Gross margin increased 310 basis points and adjusted operating margin rose 420 basis points year over year, supported by favorable HVP mix, pricing, plant execution and SG&A leverage.
• West is investing to support future growth through HVP finishing-capacity expansions in Europe and the U.S., while targeting CapEx of 6%–8% of revenue. New capacity is expected to come online over roughly 18–24 months, with existing facilities expected to support near-term demand.
• West Vantage remained in transition, with organic revenue down 6.6% as legacy programs, including a CGM program, rolled off faster than new higher-value programs ramped. In addition, the SmartDose 3.5 divestiture is expected to create an approximately 290-basis-point headwind to reported growth in 2027, while free cash flow was down about 5% year to date due mainly to higher receivables and inventory.

West Pharmaceutical Services Stock Performance

Shares of NYSE WST traded up $16.40 during mid-day trading on Thursday, hitting $420.04. 1,172,613 shares of the company were exchanged, compared to its average volume of 804,123. The company has a quick ratio of 2.12, a current ratio of 2.82 and a debt-to-equity ratio of 0.07. The stock has a 50 day simple moving average of $365.32 and a 200-day simple moving average of $311.80. West Pharmaceutical Services has a 1-year low of $223.83 and a 1-year high of $438.27. The firm has a market cap of $29.56 billion, a price-to-earnings ratio of 53.75, a price-to-earnings-growth ratio of 2.75 and a beta of 1.13.

West Pharmaceutical Services Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, November 18th. Stockholders of record on Wednesday, November 11th will be paid a dividend of $0.26 per share. This represents a $1.04 annualized dividend and a dividend yield of 0.2%. This is a boost from West Pharmaceutical Services's previous quarterly dividend of $0.22. The ex-dividend date is Tuesday, November 10th. West Pharmaceutical Services's dividend payout ratio (DPR) is currently 13.32%.

Analysts Set New Price Targets

Several analysts recently commented on the stock. Barclays upped their price target on shares of West Pharmaceutical Services from $400.00 to $440.00 and gave the company an "overweight" rating in a research report on Wednesday, October 7th. BNP Paribas Exane began coverage on shares of West Pharmaceutical Services in a research report on Monday, July 13th. They set an "outperform" rating and a $447.00 price objective on the stock. Citigroup lifted their price objective on shares of West Pharmaceutical Services from $400.00 to $412.00 and gave the company a "buy" rating in a research note on Monday, August 3rd. Wall Street Zen cut shares of West Pharmaceutical Services from a "buy" rating to a "hold" rating in a report on Saturday, October 24th. Finally, KeyCorp increased their target price on shares of West Pharmaceutical Services from $350.00 to $390.00 and gave the stock an "overweight" rating in a research note on Thursday, July 2nd. Twelve equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $391.17.

Insiders Place Their Bets

In other West Pharmaceutical Services news, VP Annette Favorite sold 8,135 shares of the business's stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $340.81, for a total value of $2,772,489.35. Following the transaction, the vice president directly owned 16,845 shares of the company's stock, valued at approximately $5,740,944.45. The trade was a 32.57% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In the last 90 days, insiders have sold 15,659 shares of company stock valued at $5,443,749. Company insiders own 0.60% of the company's stock.

Key Headlines Impacting West Pharmaceutical Services

Here are the key news stories impacting West Pharmaceutical Services this week:

• Positive Sentiment: Quarterly results exceeded expectations. West reported third-quarter revenue of $874.5 million, up 8.7% year over year and above the $827.1 million consensus estimate. Earnings were $2.66 per share, compared with expectations of approximately $2.18-$2.20 and $1.96 in the prior-year quarter. West Reports Third-Quarter 2026 Results
• Positive Sentiment: West raised its 2026 outlook. Full-year revenue guidance increased to $3.41 billion-$3.42 billion from $3.345 billion-$3.380 billion. Adjusted diluted EPS guidance rose to $9.38-$9.48 from $8.85-$9.05, signaling stronger expected sales, profitability and operating leverage. West Pharmaceutical Services Raises Annual Outlook
• Positive Sentiment: High-Value Product Components provided a major growth engine. Sales in this business increased 19.7% and represented 53% of quarterly sales. Management also cited margin expansion, supporting investor confidence in the company’s product mix and demand trends. West Pharma Q3 Earnings Rise on HVP Strength
• Neutral Sentiment: Investor positioning is mixed. Several large institutions increased their holdings in the latest quarter, although others reduced exposure. Analysts tracked in the reports have generally been constructive, but the median recent price target of $390 is below the current trading range.
• Negative Sentiment: Valuation and insider selling remain risks. A separate analysis argued that West may be overvalued because cash flow has lagged its valuation. In addition, reported insider activity showed sales without purchases over the past six months, potentially limiting enthusiasm after the rally. West Stock Could Be Overvalued

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc develops and manufactures components and delivery systems used in the administration and packaging of injectable medicines and other healthcare products. Its offerings include elastomer closures, seals, syringe components, drug-delivery systems, and other specialized packaging components designed to support the safety, quality, and performance of pharmaceutical products.

The company also provides contract-manufacturing services for pharmaceutical, biotechnology, and medical-device customers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.